Colon Cancer Study: Clinical Trial Evaluating Cholesterol-Lowering Drug as Treatment to Reduce Colon Cancer Risk Available at Abington Memorial Hospital

Hospital's Rosenfeld Cancer Center Seeking Clinical Trial Participants for Study Evaluating Rosuvastatin as Treatment to Reduce Colon Cancer Risk

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
We are very excited about this study's potential.

Abington, PA (PRWEB) September 06, 2012

A new National Cancer Institute (NCI) sponsored study evaluates the cholesterol drug, Rosuvastatin, (Crestor) as a treatment to reduce the risk of colon cancer. Rosuvastatin is a statin, a class of drugs that lowers cholesterol. The study, titled, “P-5: Statin Polyp Prevention Trial in Patients with Resected Colon Cancer,” is being conducted by a network of cancer research professionals, the National Surgical Adjuvant Breast and Bowel Project (NSABP), at 200 medical centers located throughout North America, including The Rosenfeld Cancer Center at Abington Memorial Hospital.

The study was developed because laboratory research and studies conducted in large populations of patients taking a statin to reduce cholesterol suggest that taking the drug may also decrease the number of colon polyps. Colon polyps can lead to colon cancer if left untreated.

The study will involve 1,740 patients who have recently been diagnosed with early stage colon cancer and who were not already taking statins for high cholesterol. Patients will be randomly assigned to one of two groups. Each group will take one pill a day for five years. One group
will receive Rosuvastatin, while the other group will receive a placebo.

“We at Abington Memorial Hospital are pleased to bring this clinical trial to our colon cancer patients,” said Willard Andrews, M.D., medical oncologist/hematologist, Abington Memorial Hospital. “We are very excited about this study’s potential.”

“There will be an estimated 102,900 new cases of colon cancer in the United States this year. In fact, colorectal cancer is the third most common cancer found in men and women in this country. We hope this trial will be an important step in reducing these numbers,” said Norman Wolmark, M.D., NSABP’s Chairman.

People recently diagnosed with a Stage I or II colon cancer who are interested in the study should call 215-481-2402 or email AMH-CareSearch(at)amh(dot)org.

NSABP
Since its beginning more than 50 years ago, NSABP has enrolled more than 140,000 women and men in clinical trials in breast and colorectal cancer. NSABP has research sites at major medical centers, university hospitals, large oncology practice groups and health maintenance organizations in the U.S., Canada, Puerto Rico, Australia and Ireland. At those sites and their
satellites, more than 5,000 physicians, nurses and other medical professionals conduct NSABP treatment and prevention studies.

About Abington Memorial Hospital
Abington Memorial Hospital is a 665-bed, acute care teaching hospital with a medical staff of more than 1,100 physicians and more than 5,600 employees. These professionals provide medical care and health services to residents of Bucks, Montgomery and Philadelphia counties.
A regional provider, Abington Memorial Hospital has the only Level II accredited trauma center in Montgomery County and offers highly specialized services in cardiac care, cancer care, neurosciences, orthopaedics and maternal/child health.


Contact

Attachments